Corcept Therapeutics - Public Comps and Valuation Multiples

Corcept Therapeutics Overview

About Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Founded

1998

HQ

Employees

500

Website

corcept.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

Last FY Revenue $675M

Last FY EBITDA $138M

EV

$3.6B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Corcept Therapeutics Financials

See Corcept Therapeutics valuation multiples based on analyst estimates

Corcept Therapeutics P&L

In the most recent fiscal year, Corcept Therapeutics reported revenue of $675M and EBITDA of $138M.

Corcept Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Corcept Therapeutics valuation multiples based on analyst estimates

	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	XXX	$675M	XXX	XXX	XXX
Gross Profit	XXX	$664M	XXX	XXX	XXX
Gross Margin	XXX	98%	XXX	XXX	XXX
EBITDA	XXX	$138M	XXX	XXX	XXX
EBITDA Margin	XXX	20%	XXX	XXX	XXX
EBIT	XXX	$137M	XXX	XXX	XXX
EBIT Margin	XXX	20%	XXX	XXX	XXX
Net Profit	XXX	$141M	XXX	XXX	XXX
Net Margin	XXX	21%	XXX	XXX	XXX
Net Debt	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Corcept Therapeutics including revenue, profitability, and margin analysis across different time periods. In the most recent fiscal year, Corcept Therapeutics achieved $675M in revenue and $138M in EBITDA.
Financial Metric	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	Analyst estimates available to subscribers	$675M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	Analyst estimates available to subscribers	$664M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	Analyst estimates available to subscribers	98.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	Analyst estimates available to subscribers	$138M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	Analyst estimates available to subscribers	20.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	Analyst estimates available to subscribers	$137M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	Analyst estimates available to subscribers	20.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	Analyst estimates available to subscribers	$141M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	Analyst estimates available to subscribers	20.9% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Corcept Therapeutics

This financial data table provides comprehensive performance metrics for Corcept Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Fiscal Year Performance

In the most recent fiscal year, Corcept Therapeutics reported $675M in total revenue.
Fiscal year EBITDA was $138M.
The company maintained a gross profit margin of 98.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 20.5%.
Net profit margin reached 20.9% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Corcept Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Corcept Therapeutics Stock Performance

Corcept Therapeutics has current market cap of $4.0B, and EV of $3.6B.

Market Cap Evolution

Corcept Therapeutics Stock Data

As of January 5, 2026, Corcept Therapeutics's stock price is $38.

See Corcept Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$3.6B	$4.0B	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Corcept Therapeutics Valuation Multiples

Corcept Therapeutics's trades at 5.3x EV/Revenue multiple, and 26.1x EV/EBITDA.

See valuation multiples for Corcept Therapeutics and 15K+ public comps

Corcept Therapeutics Financial Valuation Multiples

As of January 5, 2026, Corcept Therapeutics has market cap of $4.0B and EV of $3.6B.

Equity research analysts estimate Corcept Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Corcept Therapeutics's P/E ratio is not available.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$4.0B	XXX	$4.0B	XXX	XXX	XXX
EV (current)	$3.6B	XXX	$3.6B	XXX	XXX	XXX
EV/Revenue	n/a	XXX	5.3x	XXX	XXX	XXX
EV/EBITDA	n/a	XXX	26.1x	XXX	XXX	XXX
EV/EBIT	n/a	XXX	26.3x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	n/a	XXX	28.5x	XXX	XXX	XXX
EV/FCF	n/a	XXX	18.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Corcept Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Corcept Therapeutics Margins & Growth Rates

Corcept Therapeutics's revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.1M for the same period.

Corcept Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Corcept Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Corcept Therapeutics and other 15K+ public comps

Corcept Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	n/a	XXX	n/a	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	20%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	n/a	XXX	n/a	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	n/a	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.4M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	37%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	78%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial